FINANCE: North Tyneside PCT, Northumberland CT and Newcastle PCT are facing overspending risks in relation to Newcastle upon Tyne Hospitals Foundation Trust, largely attributable to use of Lucentis (ranibizumab injection).

The North of Tyne PCT Cluster July finance report states: “The Newcastle upon Tyne Hospitals FT contract is marginally overperforming in North Tyneside PCT (£142K) and Northumberland CT (£189K).

“Activity for Newcastle PCT is underperforming against contract but adjusted for cost improvement requirements, shows an overspend of £215K against budget.

“Initial activity for the first two months suggests risks mainly in outpatients and outpatient procedures, largely as a result of Lucentis activity performing higher than expected which transferred back to PCTs from specialised commissioning in 2012-13.”